Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA OKs trials for Isotechnika eye drug
ISA247, which is referred to as LX211 by Lux, will be investigated in the oral capsule formulation for the treatment of active and control of uveitis, an autoimmune
ISA247, which is referred to as LX211 by Lux, will be investigated in the oral capsule formulation for the treatment of active and control of uveitis, an autoimmune
Lilly will pay Applied NeuroSolutions $2 million, including a $500,000 equity investment in the company and will receive annual research and development support as part of the deal.
Aplindore was initially developed by Wyeth for schizophrenia and has been studied in six phase I and phase II clinical trials. The drug demonstrated excellent brain receptor occupancy
Barr plans to market pravastatin tablets in 10mg, 20mg, and 40mg strengths and has received tentative approval for 80mg strength and plans to launch this strength following the
Loughlin was effective immediately. He will be responsible for establishing EH&S policies and standards, setting and tracking performance goals, and ensuring global consistency within the company’s EH&S and
The two companies signed a license agreement in 2004 to research and develop disease-modifying therapeutic drugs for Alzheimer's disease and other memory-related disorders utilizing Acumen's amyloid-derived diffusible ligand
Earlier in the year, a GlaxoSmithKline sponsored a study discovered that its Relenza antiviral treatment is less likely to lead to drug-resistant flu strains than Tamiflu. Roche said
This is the second pivotal clinical study of Clolar in adult patients with acute myelogenous leukemia (AML) to commence this year, and Genzyme expects it to provide substantial
“MitoQ blocks the effects of oxidation, a chemical reaction that generates oxygen free radicals, which can attack and destroy cells. We achieved enrollment in this phase II trial
According to Sanofi Pasteur, the vaccines unit of Sanofi-Aventis, it has been able to produce more vaccine then it had originally projected in response to customer demand. The